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Abstract  
 
We undertook a systematic review of the pre-clinical and clinical literature for studies 
investigating the relationship between platinum and taxane resistance. Medline was 
searched for 1) cell models of acquired drug resistance reporting platinum and taxane 
sensitivities and 2) clinical trials of platinum or taxane salvage therapy in ovarian cancer. 
137 models of acquired drug resistance were identified. 68.1% of cisplatin-resistant cells 
were sensitive to paclitaxel and 66.7% of paclitaxel-resistant cells were sensitive to 
cisplatin. A similar inverse pattern was observed for cisplatin vs docetaxel, carboplatin vs 
paclitaxel and carboplatin vs docetaxel. These associations were independent of cancer 
type, agents used to develop resistance and reported mechanisms of resistance. 65 eligible 
clinical trials of paclitaxel-based salvage after platinum therapy were identified. Studies 
of single agent paclitaxel in platinum-resistant ovarian cancer where patients had 
previously recieved paclitaxel had a pooled response rate of 35.3% n=232, compared to 
22% in paclitaxel naïve patients n=1918 (p<0.01 Chi-squared). Suggesting that pre-
treatment with paclitaxel may improve the response of salvage paclitaxel therapy. The 
response rate to paclitaxel/platinum combination regimens in platinum-sensitive ovarian 
cancer was 79.5% n=88 compared to 49.4% n=85 for paclitaxel combined with other 
agents (p<0.001 Chi-squared), suggesting a positive interaction between taxanes and 
platinum. Therefore the inverse relationship between platinum and taxanes resistance 
seen in cell models is mirrored in the clinical response to these agents in ovarian cancer. 
An understanding of the cellular and molecular mechanisms responsible would be 
valuable in predicting response to salvage chemotherapy and may identify new 
therapeutic targets. 
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Introduction 
 
The anti-tumour activity of cisplatin was first observed in the 1960s. The first cancer 
patient received cisplatin in April 1971. Cisplatin quickly progressed through clinical 
trials becoming the first platinum compound approved for cancer therapy and has been 
used widely in cancer patients since 1978 
1
. Cisplatin binds to the DNA strand hindering 
both DNA replication and RNA translation and eventually triggering apoptosis. Many 
cisplatin analogues were developed in an attempt to improve on cisplatin. Carboplatin 
was introduced into the clinic in 1992. Like cisplatin, carboplatin also binds to the DNA 
strand but in contrast it has a more favourable toxicity profile making it a popular choice 
in the clinic. However, cisplatin has been shown to have increased therapeutic efficacy in 
many tumours compared to carboplatin 
2
. Cisplatin or carboplatin are currently used as 
part of combination chemotherapy for the treatment of ovarian, testicular, head and neck 
cancers and gastro-esophageal cancers. 
 
Paclitaxel, derived from the bark of the Pacific yew tree Taxus brevifolia, was first shown 
to have antitumour activity in 1971
3
. All antimicrotubule agents disrupt mitosis however, 
paclitaxel was the first to stabilise polymerised microtubules in contrast to previous 
antimicrotubule agents such as vincristine and colchicine which depolymerise 
microtubules 
4
. The first phase I clinical trials of paclitaxel began in 1983 but were slow 
to progress with many paclitaxel hypersensitivity reactions reported and problems with 
supply of the drug. Paclitaxel is now produced in a renewable manner from plant cell 
culture 
5
. Concurrently a semi synthetic analogue of paclitaxel, docetaxel, was developed 
entering clinical trials in 1990 
6
. Paclitaxel or docetaxel are currently used as part of 
combination chemotherapy for the treatment of ovarian, breast and non-small cell lung 
cancers 
7
. 
 
Initial responsiveness to cisplatin therapy is high, however the majority of patients 
ultimately relapse with resistant disease. Mechanisms of cisplatin resistance characterised 
in resistant cell models include, decreased cellular accumulation of drug, increased levels 
of glutathione, increased levels of DNA repair and increased anti-apoptotic activity 
8
. 
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Similarly, many patients will relapse with disease resistant to paclitaxel therapy. 
Paclitaxel resistance can be mediated by P-glycoprotein export decreasing the cellular 
accumulation 
9
. Other mechanisms of paclitaxel resistance include altered expression or 
post-translational modification of β-tubulin, the target of paclitaxel, or other microtubule 
regulatory proteins. Any alteration in microtubule dynamics, paclitaxel binding sites or 
signalling pathways up or downstream of microtubule polymerisation can potentially 
mediate paclitaxel resistance 
10
. 
 
Due to their differing mechanisms of action platinums and taxanes are often combined in 
cancer therapy. However, work in cell lines suggests that alternating between the two 
classes of drugs may be beneficial. Paclitaxel pre-treatment has also been shown to 
sensitise platinum-resistant cell lines 
11-13
. Work in our laboratory has also suggested that 
when cells become resistant to platinum they often become sensitive to taxanes 
14,15
. 
Preliminary reading of the literature suggested that the reverse is also true i.e. that taxane-
resistant cell lines can be sensitive to platinum 
9,16
. We undertook this systematic review 
to examine the pre-clinical evidence exploring the relationship between platinum and 
taxane resistance, and to examine the clinical evidience for taxane activity in patients 
with platinum-resistant cancer and the reverse, platinum activity in taxane-resistant 
cancer. 
 
Methods 
 
We conducted literature searches for pre-clinical and clinical studies using Medline. 
Review articles and articles not published in English were excluded. Conference 
presentations and abstracts were not included. The literature searches were last updated in 
May 2007. 
 
Literature searches for pre-clinical studies 
 
Medline was searched for human cell lines with acquired drug resistance describing the 
cross-resistance between at least two of the following compounds, cisplatin, carboplatin, 
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paclitaxel and docetaxel in models of acquired drug resistance. The following were used 
as keywords, ‘cisplatin’, ‘carboplatin’, ‘taxol’, ‘paclitaxel’, ‘taxotere’, ‘docetaxel’, ‘cross 
resistance’, ‘cross resistant’, ‘resistant’, ‘resistance’, ‘toxicity’ and ‘cell line’. Resistance 
studies looking at a panel of cancer cell lines and the relative resistance between them 
were excluded, as these studies examine innate platinum resistance and not resistance 
developed from chemotherapy. Resistant cell lines developed with platinums and taxanes 
were the most common found but resistant cell models developed to other compounds 
were included if they had cross resistance data for two or more compounds of interest. 
Resistant cell lines resulting from transfection were excluded. The name of each cell line 
found was also used as a medline keyword search to find cross resistance data over 
multiple publications. In some cases the same resistant cell line has been published with 
cross resistance data in multiple publications. In this case the key publication has been 
referenced. 
 
Literature searches for clinical studies 
 
Medline was searched for all controlled clinical trials using paclitaxel alone or in 
combination as treatment for patients who had previously received cisplatin or 
carboplatin based chemotherapy. Medline was also searched for clinical trials using 
cisplatin for the treatment of patients who had previously received taxanes. ‘paclitaxel’, 
‘cisplatin’, ‘carboplatin’, ‘platinum’, ‘taxane’, ‘salvage’, ‘resistant’, ‘resistance’, 
‘refractory’, ‘second line’ were used as keywords and studies were limited to any clinical 
trial type. The reference lists in included papers were also searched for additional studies. 
Studies using platinum or taxanes as first line therapy were excluded. Studies where prior 
chemotherapy treatment was not itemised were excluded. Studies where the platinum 
resistance status was not defined were also excluded. Studies including both cisplatin or 
paclitaxel pre-treated and chemotherapy naïve patients were eligible as long as the results 
for pre-treated patients were reported separately to allow data extraction.  
 
We used the pooled response rate as a measure of drug activity. The pooled response rate 
for each cohort described was the combined complete and partial response rates of each 
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study based on the published response rate, assuming a standardised measure of response 
was used in the study. Patients recruited earlier than 1995 were assumed to be taxane 
naïve as platinum/paclitaxel combination therapy was only adopted as first-line therapy 
for ovarian cancer after several successful trials in 1996 showed the superiority of this 
regimen compared to the then standard therapy of cisplatin/cyclophosphamide 
17,18
. This 
group of patients were analysed separately as there is the possibility that this group may 
have received prior paclitaxel salvage therapy. There was no difference in response rate 
or other patient characteristics between these two groups.  
 
Statistics  
 
Linear regressions were performed on the scatter plots of the pre-clinical data. R values 
were calculated to show either a positive or negative correlation. The chi-squared test was 
used to test for significant differences between the pooled clinical data. p values of less 
than 0.05 were considered significant. 
 
Results and Discussion 
 
Platinum and taxane resistance in pre-clinical studies 
 
Resistant cell models are developed in the laboratory by repeatedly exposing cancer cells 
in culture to chemotherapy. The surviving resistant cells are then compared to the 
parental sensitive cells using a cell viability assay such as the MTT or clonogenic assay. 
The platinum and taxane sensitivity of these paired cell lines is usually determined by 
exposing them to a range of drug concentrations and then assessing cell viability. The 
IC50 (drug concentration causing 50% growth inhibition) for these paired cell lines can be 
used to determine the increase in resistance known as fold resistance by the following 
equation:- 
 
Fold Resistance = IC50 of Resistant Cell Line / IC50 of Parental Cell Line 
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The literature search for models of acquired resistance which report cross resistance data 
for both cisplatin and paclitaxel identified 137 cell lines 
9,11,13-16,19-83
. For each cell line 
the fold paclitaxel resistance was plotted against the fold cisplatin resistance, allowing an 
analysis of the pattern of cross resistance between the two compounds (Figure 1A). The 
definition of cross resistance is a matter of debate in the literature. Some studies consider 
two drugs cross-resistant only if a similar level of resistance is observed. Studies which 
have developed cell lines from patients before and after chemotherapy have found that 
drug resistance in the clinic typically produces resistance of 2 to 3 fold 
84,85
. For the 
purposes of this review we have defined cross resistance between cisplatin and paclitaxel 
as greater than or equal to 2-fold resistance to both drugs. This definition is therefore 
based on what would be clinically observed as cross resistance. 13.9% of cell lines found 
in the literature review were below 2-fold resistance to both compounds and therefore 
classed as non-resistant indicated with black stars in Figure 1A.  
 
It is the minority of cell models of acquired resistance shown in Figure 1A which are 
cross-resistant (open circles) to both cisplatin and paclitaxel (16.8%). The majority of 
cells are either non-cross resistant (grey circles 40.9%), with no gain of resistance to the 
other compound, or hypersensitive (black circles 28.5%) becoming more sensitive than 
the parental cancer cell line they were derived from. 71 cell lines were resistant to 
cisplatin, 48 of these were non-cross resistant or hypersensitive to paclitaxel (67.6%). 69 
cell lines were resistant to paclitaxel, 46 of these were non-cross resistant or 
hypersensitive to cisplatin (66.6%). This suggests an inverse relationship between 
cisplatin and paclitaxel resistance in resistant cell models where resistance to one leads to 
sensitivity to the other. The resistant cell lines found in the systematic review were 
diverse in type of carcinoma (Figure 1B). Ovarian (45.3%) and SCLC (21.2%) were the 
most common carcinomas used to develop cell lines, however, the other 16 types of 
carcinoma suggest that the inverse relationship between cisplatin and paclitaxel resistance 
is not cell type specific and could apply to all cancers. The chemotherapeutics used to 
develop the resistant models were also diverse, the most common were cisplatin (37.2%) 
and paclitaxel (20.4%) (Figure 1C). The other 31 agents are diverse mechanistically 
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suggesting that when cells become resistant to any agent there are two distinct paths 
available, one which leads to cross resistance to cisplatin and the other to paclitaxel.  
 
The methods used to determine the IC50 of the resistant models, as well as the exposure 
time of the toxicity assays also varied between the studies found in this systematic 
review. The consistency of the inverse relationship between cisplatin and paclitaxel 
resistance despite such experimental variability suggests a that there is a fundamental 
molecular process involved in this relationship. We then sought to examine the resistance 
relationship between other platinum and taxane chemotherapy agents. 
 
To examine if the inverse relationship between cisplatin and paclitaxel extended to other 
platinum and taxane drugs, the cross resistance pattern between cisplatin vs docetaxel, 
carboplatin vs paclitaxel and carboplatin vs docetaxel were examined. The literature 
search for models of acquired resistance which report cross resistance data for both 
cisplatin and docetaxel identified 59 cell lines 
14,16,19,23,30,31,43,44,49,54,58,74,75,77,80-82,86-95
. A 
similar inverse relationship was observed between cisplatin and docetaxel as for cisplatin 
and paclitaxel (Figure 2A). 20 cell lines were resistant to cisplatin, 14 of these were non-
cross resistant or hypersensitive to docetaxel (70.0%). 26 cell lines were resistant to 
docetaxel, 20 of these were non-cross resistant or hypersensitive to cisplatin (76.9%). A 
similar array of cancer types and selecting agents were also found. 47 cell lines were 
identified for carboplatin vs paclitaxel 
11,14,22,24,28,30,41,42,44,52,54,56, 62,67,71,72,76-79,96-107
. A 
similar inverse relationship was observed between carboplatin and paclitaxel (Figure 2B). 
31 cell lines were resistant to carboplatin, 19 of these were non-cross resistant or 
hypersensitive to paclitaxel (67.6%). 18 cell lines were resistant to paclitaxel, 6 of these 
were non-cross resistant or hypersensitive to carboplatin (33.3%). This last percentage is 
unusually low compared to the other inverse relationships due to the limited number of 
cell lines found in the systematic review process.  20 cell lines were identified for 
carboplatin vs docetaxel 
14,23, 30,44,54,77,87,89,94,97,99,100,104
. A similar inverse relationship was 
observed between carboplatin and docetaxel (Figure 2C). 10 cell lines were resistant to 
carboplatin, 6 of these were non-cross resistant or hypersensitive to docetaxel (60.0%).  
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9 cell lines were resistant to docetaxel, 5 of these were non-cross resistant or 
hypersensitive to carboplatin (55.6%). 
 
To highlight how different the inverse relationship between platinum and taxanes is to 
cross-resistance between agents the pattern of cisplatin and carboplatin as well as 
paclitaxel and docetaxel were analysed. The literature search for models of acquired 
resistance which report cross resistance data for both cisplatin and carboplatin identified 
98 cell lines of which 76.5% were cross resistant (Figure 3A)
 11,14,23,24,28,30,41,42,44,54,62,72,76-
78,87,89,94,96-98,100-103,106-135
. 45 cell lines were also identified for paclitaxel and docetaxel of 
which 71.1% were cross resistant (Figure 3B) 
14,16,19,23,30,31,43,44,54,90,74,75,77,80-82,95,99,104,136-
139
. Cross resistance was observed between these similar compounds over a large range of 
fold resistances.  A large array of cancer types were represented in both these 
comparisons. The selecting agents used in the cell lines reporting platinum cross resistant 
data were predominately platinum based, cisplatin 71.4% and carboplatin 7.1%. The 
selecting agents in the taxane comparison were more diverse with paclitaxel and 
docetaxel representing 24.4 and 11.1% of cell lines respectively. 
 
As this inverse relationship between platinum and taxanes occurs in so many resistant 
cell models the individual mechanisms of resistance are many and varied. The major 
mechanisms of cisplatin resistance in cells with a lack of cross resistance to paclitaxel 
include, increased glutathione 
25,81
 and decreased accumulation of the drug 
21,24,79
. 
However, some models have neither increased glutathione or decreased accumulation of 
cisplatin yet are hypersensitive to paclitaxel 14. This suggests that cisplatin-resistant cell 
lines are sensitive to paclitaxel irrespective of their major mechanism of platinum 
resistance. The ABC transporter P-glycoprotein transports paclitaxel out of a cell but 
does not transport cisplatin. Many of the paclitaxel-resistant cell lines, with a sensitivity 
to cisplatin, have increased P-glycoprotein expression leading to increased efflux of 
paclitaxel 
9
, but others do not 
83
. This suggests that the sensitivity to cisplatin is 
independent of P-glycoprotein mediated resistance, and that there is a fundamental 
molecular process involved in this relationship that is yet to be elucidated. An 
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understanding of this response could lead to improved treatment strategies for both 
cisplatin- and paclitaxel-resistant cancer. 
 
Pre-treatment with a low dose of paclitaxel can also sensitise platinum-resistant lung 
cancer cells to platinum treatment 
11-13
. These cisplatin resistant cell lines are not 
hypersensitive to paclitaxel, they are non-cross resistant showing the same level of 
resistance as the parental cell line. Maximal sensitisation was achieved with a low 10 
ng/ml dose of paclitaxel, whereas a paclitaxel induces a G2/M block at doses greater than 
12.5 ng/ml. The sensitisation due to paclitaxel was therefore independent of the cell cycle 
mediated effect of the drug 
12
. This suggests that other signalling pathways, independent 
of the cell cycle effects of paclitaxel, may be involved in the sensitisation to cisplatin 
treatment.  
 
This same sensitisation effect has also been observed in platinum-resistant A2780/CP 
ovarian carcinoma cells with 3nM paclitaxel pre-treatment 
140
. Again, the A2780/CP cells 
are not hypersensitive to paclitaxel but non-cross resistant 
41
. Pre-treatment with 
paclitaxel therefore has the potential to render cisplatin-resistant cells sensitive to 
platinum therapy. This systematic review has shown that 67.6% of cisplatin-resistant cell 
lines are hypersensitive or non-cross resistant to paclitaxel. The clinical challenge is to 
identify which patients are likely to respond to single agent paclitaxel and those who 
require paclitaxel pre-treatment before recommencing platinum therapy. 
 
The success of paclitaxel pre-treatment has also been demonstrated in an animal model 
141
. In KF28 chemotherapy naïve cells implanted into nude mice the sequence of 
paclitaxel then cisplatin or the paclitaxel/cisplatin combination was superior to either 
agent alone or cisplatin first followed by paclitaxel. In KF13 cisplatin resistant cells in 
the same nude mice model, single agent paclitaxel and any paclitaxel combination 
regimen was superior to cisplatin treatment 
141
. This is what was predicted to occur from 
toxicity testing of the KF13 cells in vitro, the cells are 4.84 fold resistant to cisplatin but 
hypersensitive to paclitaxel 0.56 fold 
21
. The cell models summarised in this systematic 
review have shown that there is an inverse relationship between cisplatin and paclitaxel 
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resistance. The question we would now like to examine is does this pattern extend to the 
clinical treatment of drug-resistant cancer? 
 
Paclitaxel in the treatment of patients with platinum-resistant ovarian cancer 
 
Cisplatin combination chemotherapy is the cornerstone of treatment of ovarian 
carcinomas. Initial platinum responsiveness in ovarian cancer is high, but up to 80% of 
patients will eventually relapse and become cisplatin resistant 
142
. Clinical platinum 
resistance is variably defined in the clinic and as such it is difficult to make comparisons 
of treatment activity between trials. However, many second-line ovarian carcinoma 
studies use Markman’s criteria 
143
 where disease progression with a platinum free interval 
of less than 6 months is considered platinum resistant. Paclitaxel resistance is a concept 
that is not clearly defined in the literature. Where paclitaxel resistance is defined it is 
usually defined in the same manner as platinum resistance, disease progression with a 
taxane-free interval of < 6 months. 
 
Paclitaxel has been used as a single agent and in combination with other 
chemotherapeutics for the treatment of platinum-resistant ovarian cancer. Ovarian 
carcinoma was chosen for this analysis as our preliminary literature searches showed it 
had by far the most studies of paclitaxel salvage therapy in platinum-resistant patients. 
Furthermore, platinum resistance is usually clearly defined in ovarian cancer. Hence our 
study populations were more likely to be homogenous. Other platinum-resistant 
carcinomas which have been treated with paclitaxel based salvage therapy include 
testicular 
144-147
, NSCLC 
148,149
, urothelial 
150
, bladder 
151
 and endometrial carcinomas 
152
.  
 
Our search of the literature for paclitaxel salvage therapy in platinum-resistant ovarian 
carcinoma identified 98 studies. 56 studies were using single agent paclitaxel, 26 studies 
a paclitaxel/platinum combination and 16 studies were other paclitaxel based 
combination chemotherapy. In order to analyse if the inverse relationship between 
cisplatin and paclitaxel resistance observed in resistant cell models is apparent in clinical 
trials the studies were divided into two groups, paclitaxel naïve ovarian cancer or 
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paclitaxel pre-treated ovarian cancer. The patients from these studies were then divided 
into platinum resistant or platinum sensitive groups where resistance was defined as a 
platinum free interval of < 6 months. Those studies which did not define the platinum-
free interval of their patients were excluded. Those studies which had paclitaxel both 
naïve and pre-treated patients and reported a combined response rate were excluded. Of 
the 98 studies identified in the literature search 65 were suitable for analysis. These 
studies were all Phase I and II controlled clinical trials.  
 
Figure 4A is a summary of the pooled response rate for each cohort of patients divided on 
their platinum-resistance status and paclitaxel pre-treatment status. As expected the 
response rate of platinum-sensitive patients is higher than the platinum-resistant group 
across both paclitaxel groupings. What was unexpected was platinum-resistant patients 
who have previously received paclitaxel therapy respond better to single agent paclitaxel 
(RR 35.3% n = 232) than paclitaxel naïve patients (RR 22.7% n = 1918) (p <0.01 Chi-
squared). Similarly in platinum-sensitive patients the paclitaxel pre-treated cohort (RR 
57% n = 26) had a higher response rate than the paclitaxel naïve (RR 38.8% n = 520), 
however this was not significant due to low patient numbers. Usually if patients have 
received a drug and experienced disease progression, they are less likely to respond to 
therapy with a subsequent exposure to the same drug. Although one must be cautious in 
interpreting these summary findings due to the potential for biases in pooling of patients 
across studies, if the findings do reflect the true clinical response to these agents they 
suggest that initial co-treatment with platinum and paclitaxel may improve the outcome 
of paclitaxel salvage therapy. Paclitaxel may be acting as a response modifier, altering 
the kind of platinum resistance rendering the cancer sensitive to paclitaxel therapy. This 
hypothesis could be tested prospectively in a well designed clinical trial addressing drug 
sequencing. 
 
Table 1 examines the patient characteristics from the paclitaxel naïve and pre-treated 
cohorts to determine if any other factor may have contributed to the unexpected higher 
response rate of the paclitaxel pre-treated patients. The cohorts of patients have very 
similar age, performance status, FIGO stage, and number of cycles of prior 
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chemotherapy. There was however a histological difference between the two groups, in 
the paclitaxel naïve group 59% were serous adenocarcinomas whereas in the paclitaxel 
pre-treated group 78% were serous adenocarcinomas. Serous histology has been shown to 
be prognostic of response to paclitaxel salvage chemotherapy in platinum pre-treated 
ovarian cancer 
153,154
. Only 16 of the 30 studies in the paclitaxel naïve group reported 
tumour histology representing 39.2% of patients, therefore the lack of data in this cohort 
may be responsible for this apparent difference between the two groups. Studies which 
had serous histology of 60% or less were then eliminated from this group leaving 6 
studies with a combined serous histology of 70% representing 353 patients 
155-160
. This 
subgroup of paclitaxel naïve patients had a pooled response rate of 21% (platinum 
resistant patients) and 39% (platinum sensitive patients), similar to that of the whole 
paclitaxel naïve cohort. This result suggests that the higher response rate of the paclitaxel 
pre-treated cohort is not explained entirely by the higher percentage of serous histology. 
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Table 1 - Single Agent Paclitaxel in Platinum Pre-treated Ovarian Carcinoma 
 Paclitaxel Naïve (2438 patients) 
30 Studies 
Paclitaxel Pre-treated (258 patients) 
8 Studies 
Pooled Response Rate Platinum Resistant 436/1918 (22.7%) 
Platinum Sensitive 202/520 (38.8%) 
Platinum Resistant 82/232 (35.3%) 
Platinum Sensitive 15/26 (57.7%) 
 % Data*  % Data*  
Age 95.5% Weighted Mean 57.65 84.9% Weighted Mean 61.88 
WHO Performance 
Status 
90.0% 0 – 2 – 97% 
3+ - 3% 
47.3% 0 – 2 – 97.6% 
3+ - 2.3% 
FIGO Stage 15.0% Stage I-II – 7% 
Stage III-IV – 93% 
58.1% Stage I-II – 9.5% 
Stage III-IV – 90.5% 
Cycles Prior 
Chemotherapy 
96.6% 1-2 Cycles – 61.8% 
3+ Cycles – 38.2% 
67.8% 1-2 Cycles – 65.7% 
3+ Cycles – 34.25% 
Histology 39.2% Serous – 58.9% 
Non Serous – 41.1% 
76.7% Serous – 78% 
Non Serous – 22% 
References 155-182 156, 183-189 
* Percentage of patients where study reported each characteristic 
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The response rate of single agent paclitaxel in platinum-resistant ovarian cancer (22.7%) 
may seem low for a drug which appears to be non-cross resistant in the platinum-resistant 
cell models. However, this response rate compares favourably to the reported response 
rate of the potentially cross-resistant oxaliplatin in platinum-resistant ovarian cancer (9%) 
examined in a recent review 
190
.  
 
Figure 4B summarises the response of ovarian cancer to salvage paclitaxel combination 
therapy. The studies have been divided into two groups: combination regimens which 
include a platinum compound and those which do not. These are further subdivided into 
paclitaxel naïve or pre-treated and platinum resistant or sensitive groupings. Here, the 
pooled response rate of paclitaxel naïve platinum-resistant patients to paclitaxel 
combination therapy paclitaxel/other 27.4% and paclitaxel/platinum 32% are higher 
compared to paclitaxel monotherapy (22.7% RR), however this difference is not 
significant. Interestingly, the response of paclitaxel naïve platinum-sensitive patients to 
platinum/paclitaxel combination therapy (79.5% n = 88) is also superior to paclitaxel 
combined with other agents (49.4% n = 85) (p < 0.001 Chi-squared). This result is again 
surprising as patients resistant to platinum would be considered to be less likely to 
respond to a platinum containing regimen than a non-platinum regimen. This suggests 
that the combination of platinum and taxanes may be additive in achieving a higher 
response rate in a platinum resistant cohort. However, there does not appear to be any 
benefit of pre-treatment with paclitaxel as observed in the response to single agent 
paclitaxel (Figure 4A). Table 2 examines the patient characteristics across the different 
cohorts. The only apparent difference is a lower percentage of serous histology in the 
paclitaxel/platinum cohorts (~ 60%) versus the paclitaxel/other cohorts (~70%). This 
difference would suggest that the paclitaxel/other cohort should have a higher response 
rate if serous histology was a significant predictive factor 
153,154
. However, the 
paclitaxel/platinum cohort is the group with the higher response rate. Suggesting that this 
response may be due a positive interaction between agents rather than any difference in 
patient characteristics. 
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Table 2 -Combination Paclitaxel in Platinum Pre-treated Ovarian Carcinoma 
Paclitaxel Naïve 
 
Paclitaxel/Other (300 patients) 
8 Studies 
Paclitaxel/Platinum (138 patients) 
8 Studies 
Pooled Response Rate Platinum Resistant 59/215 (27.4%) 
Platinum Sensitive 42/85 (49.4%) 
Platinum resistant 15/47  (32%) 
Platinum sensitive 70/88 (79.5%) 
 % Data*  % Data*  
Age 100% Weighted Mean 58.28 100% Weighted Mean 55.92 
WHO Performance Status 97% 0 – 2 – 100% 
3+ - 0% 
89.1% 0 – 2 – 100% 
3+ - 0% 
FIGO Stage 57.6% Stage I-II – 4.6% 
Stage III-IV – 95.4% 
37.7% Stage I-II – 18% 
Stage III-IV – 82% 
Cycles Prior 
Chemotherapy 
100% 1-2 Cycles – 90.3% 
3+ Cycles – 9.7% 
100% 1-2 Cycles – 100% 
3+ Cycles – 0% 
Histology 47.6% Serous – 70% 
Non Serous – 30% 
98% Serous – 60% 
Non Serous – 40%  
References 163,170,191-196 197-204 
 
Paclitaxel Pre-treated Paclitaxel/Other (109 patients) 
3 Studies 
Paclitaxel/Platinum (261 patients) 
8 Studies 
Pooled Response Rate Platinum Resistant 22/100 (22%) 
Platinum Sensitive 2/9 (22%) 
Platinum resistant 3/8 (37.5%) 
Platinum sensitive 197/253(77.8%) 
 % Data  % Data  
Age 100% Weighted Mean 56.66 76.2% Weighted Mean 56.98 
WHO Performance Status 100% 0 – 2 – 100% 
3+ - 0% 
50.5% 0 – 2 – 100% 
3+ - 0% 
FIGO Stage 15.5% Stage I-II – 17.6% 
Stage III-IV – 82.3% 
46% Stage I-II – 18% 
Stage III-IV – 82% 
Cycles Prior 
Chemotherapy 
100% 1-2 Cycles – 100% 
3+ Cycles – 0% 
90% 1-2 Cycles – 96% 
3+ Cycles – 4% 
Histology 68.8% Serous – 73% 
Non Serous – 27% 
72.8% Serous – 61.5% 
Non Serous – 38.5% 
References 205-207 197,202,204,208-212 
* Percentage of patients where study reported each characteristic 
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Platinum in the treatment of patients with taxane-resistant cancers 
 
Taxane resistance is not discussed as widely in the literature as platinum resistance. 
However, a small group of studies have examined platinum salvage therapy for taxane 
resistant cancers. The most common carcinoma examined is ovarian, where the majority 
of patients have failed combination platinum/taxane therapy 
213,214,186,215
. There are 
several studies which have platinum-naïve patients receiving platinum salvage after 
taxane therapy 
216,217,218
 but there are not enough studies from a single type of carcinoma 
to pool data to allow comparisons to be made. 
 
Molecular Mechanism of Inverse Relationship between Platinum and Taxanes 
 
From the systematic review of resistant cell models it appears that the observed inverse 
relationship between platinums and taxanes is independent of the currently known major 
mechanisms of resistance to both agents. Cisplatin is known to bind to microtubules and 
alter their dynamics 
219
, which may contribute to paclitaxel hypersensitivity in cisplatin 
resistant cell lines. Many cisplatin-resistant cell models could have alterations in tubulin 
or microtubule dynamics but this is not often studied. One study found that paclitaxel 
pre-treatment of their cisplatin-resistant cell lines increased the accumulation of cisplatin 
and was associated with tubulin alterations 
79
. If paclitaxel-resistant cell lines have 
similar tubulin alterations they may accumulate more cisplatin and become more 
sensitive to cisplatin treatment. KF28TX and KFr13TX paclitaxel-resistant cells have 
increased accumulation of cisplatin associated with cisplatin sensitivity 
21
. 
 
Many molecular markers will be required to conclusively predict if a particular tumour is 
platinum or taxane sensitive. However, several markers have already been identified 
which could form the beginning of such a panel. DNA damaging drugs including 
cisplatin were found to be more active in wild-type p53 cells in the NCI-60 cancer cell 
line panel whereas antimitotic agents including paclitaxel were found to have limited 
activity 
220
. Gene polymorphism studies have also suggested that a mutation at Asn118 
ERCC1 is associated with a decreased risk of platinum resistance in ovarian cancer 
221
. A 
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panel of molecular markers for sensitivity to cisplatin/paclitaxel combination therapy 
comprising of IL6, Bcl-2, VEGF, ERCC1 and ABCB1 (p-glycoprotein) and 8 novel 
genes identified by microarray were examined in ovarian cancer cell lines and tumour 
samples 
222
. This study found that the novel microarray genes had a higher predictive 
power than that of the well characterised genes suggesting that there are many genes of 
unknown function which can be used as molecular markers. 
 
Conclusions 
 
This review article has highlighted an inverse relationship between platinum and taxane 
resistance. This phenomenon has been demonstrated in many resistant cell models 
diverse in type of carcinoma and agent used to develop resistance. This suggests that 
there may be a benefit in alternating between these two drugs in clinical cancer treatment. 
There is indirect clinical evidence to support this hypothesis as the response rate of single 
agent paclitaxel in platinum-resistant ovarian cancer studies is greater in patients having 
previously received paclitaxel. Paclitaxel combination therapy for platinum-resistant 
ovarian cancer is also greater when the second agent is platinum. This implies a positive 
interaction between platinums and taxanes when used in combination as well as in  
sequence. 
 
The review of the cell lines exhibiting an inverse relationship between platinum and 
taxane resistance has revealed many different mechanisms of platinum and taxane 
resistance. This suggests that the mechanism of the inverse relationship between platinum 
and taxanes is independent of the major resistance mechanisms known for both 
compounds. If the wider phenomena of what causes the inverse resistance relationship 
between these compounds can also be understood, there is the potential to screen patients 
failing all kinds of chemotherapy to assess their potential to respond to platinum or 
taxane salvage therapy.  
 
If molecular markers predicting the inverse relationship between platinum and taxanes 
can be identified in cell models using microarray and/or proteomic techniques, then these 
 19 
have the potential to be translated to the clinic and be used to identify patients likely to 
respond to platinum or taxane salvage therapy.  A predictive profile could then be used 
for individual patients to optimise their chemotherapy schedule and monitor response. An 
example of such an approach using pharmacogenomic drug resistance profiling is 
currently being explored in lung and ovarian cancer cell lines 
223
. A greater understanding 
of the molecular characteristics of responders may also identify new therapeutic targets 
for cancer therapy. 
 20 
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Figure 1 - Inverse relationship between cisplatin and paclitaxel resistance in cell lines. A) 
The fold resistance of cisplatin was plotted against the fold resistance for paclitaxel for 137 
models of acquired drug resistance. The dotted line at 1 indicates the resistance of the parent 
cell lines. The solid line at 2 indicates the level of clinical resistance. B) Diversity of cancer 
type and C) Selecting agent used in the 137 models of acquired drug resistance.
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Figure 4 – Pooled response rates of paclitaxel salvage therapy in ovarian carcinoma divided 
by platinum resistance status. A) Single agent paclitaxel divided into paclitaxel naïve or 
paclitaxel pre-treated patients. B) Combination paclitaxel therapy in paclitaxel naïve or pre-
treated patients divided into paclitaxel/platinum combination therapy or other paclitaxel 
based combination therapy. The number above each bar represents the number of patients in 
the pooled cohort.
